1-15 of 15
Johann S. de Bono
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Individualised prediction of drug response and rational combination therapy in NSCLC using artificial intelligence enabled studies of acute phosphoproteomic changes

Elizabeth A. Coker, Adam Stewart, Bugra Ozer, Anna R. Minchom, Lisa Pickard, Ruth Ruddle, Suzanne Carreira, Sanjay Popat, Mary ER. O'Brien, Florence I. Raynaud, Johann S. de Bono, Bissan Al-Lazikani, Udai Banerji
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther molcanther.0442.2021.
DOI: https://doi.org/10.1158/1535-7163.MCT-21-0442
Published: 03 April 2022
View article
PDF
Includes: Supplementary data
Journal Articles

Differences in Signaling Patterns on PI3K Inhibition Reveal Context Specificity in KRAS-Mutant Cancers

Adam Stewart, Elizabeth A. Coker, Sebastian Pölsterl, Alexandros Georgiou, Anna R. Minchom, Suzanne Carreira, David Cunningham, Mary ER. O'Brien, Florence I. Raynaud, Johann S. de Bono, Bissan Al-Lazikani, Udai Banerji
Journal: Molecular Cancer Therapeutics
Series: Author Choice
Mol Cancer Ther (2019) 18 (8): 1396–1404.
DOI: https://doi.org/10.1158/1535-7163.MCT-18-0727
Published: 01 August 2019
View article
PDF
Includes: Supplementary data
Journal Articles

Modulation of Plasma Metabolite Biomarkers of the MAPK Pathway with MEK Inhibitor RO4987655: Pharmacodynamic and Predictive Potential in Metastatic Melanoma

Joo Ern Ang, Akos Pal, Yasmin J. Asad, Alan T. Henley, Melanie Valenti, Gary Box, Alexis de haven Brandon, Victoria L. Revell, Debra J. Skene, Miro Venturi, Ruediger Rueger, Valerie Meresse, Suzanne A. Eccles, Johann S. de Bono, Stanley B. Kaye, Paul Workman, Udai Banerji, Florence I. Raynaud
Journal: Molecular Cancer Therapeutics
Series: Author Choice
Mol Cancer Ther (2017) 16 (10): 2315–2323.
DOI: https://doi.org/10.1158/1535-7163.MCT-16-0881
Published: 02 October 2017
View article
PDF
Includes: Supplementary data
Journal Articles

Plasma Metabolomic Changes following PI3K Inhibition as Pharmacodynamic Biomarkers: Preclinical Discovery to Phase I Trial Evaluation

Joo Ern Ang, Rupinder Pandher, Joo Chew Ang, Yasmin J. Asad, Alan T. Henley, Melanie Valenti, Gary Box, Alexis de Haven Brandon, Richard D. Baird, Lori Friedman, Mika Derynck, Bart Vanhaesebroeck, Suzanne A. Eccles, Stan B. Kaye, Paul Workman, Johann S. de Bono, Florence I. Raynaud
Journal: Molecular Cancer Therapeutics
Series: Author Choice
Mol Cancer Ther (2016) 15 (6): 1412–1424.
DOI: https://doi.org/10.1158/1535-7163.MCT-15-0815
Published: 02 June 2016
View article
PDF
Includes: Supplementary data
Journal Articles

Abstract CN06-04: Combination strategies

Johann S. De Bono
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (12_Supplement_2): CN06-04.
DOI: https://doi.org/10.1158/1535-7163.TARG-15-CN06-04
Published: 01 December 2015
View article
Journal Articles

Abstract PR14: Phase I trial of first-in-class ataxia telangiectasia-mutated and Rad3-related (ATR) inhibitor VX-970 as monotherapy (mono) or in combination with carboplatin (CP) in advanced cancer patients (pts) with preliminary evidence of target modulation and antitumor activity

Timothy A. Yap, Maria J. de Miguel Luken, Brent O'Carrigan, Desam Roda, Dionysis Papadatos-Pastos, David Lorente, Nina Tunariu, Raquel Perez Lopez, Sasha Gayle, Ruth Riisnaes, Ines Figueiredo, Susana Miranda, Suzanne Carreira, Fang Yang, Sharon Karan, Marina Penney, John Pollard, L. Rhoda Molife, Udai Banerji, Mohammed Asmal, Scott Z. Fields, Johann S. de Bono
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (12_Supplement_2): PR14.
DOI: https://doi.org/10.1158/1535-7163.TARG-15-PR14
Published: 01 December 2015
View article
Journal Articles

Abstract C295: Update on first-in-man trial of novel oral PARP inhibitor BMN 673 in patients with solid tumors.

Zev A. Wainberg, Johann S. de Bono, Lida Mina, Jasgit Sachdev, Lauren Averett Byers, Rashmi Chugh, Charlie Zhang, Joshua W. Henshaw, Andrew Dorr, John Glaspy, Ramesh Ramanathan
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (11_Supplement): C295.
DOI: https://doi.org/10.1158/1535-7163.TARG-13-C295
Published: 01 November 2013
View article
Journal Articles

The Association of PI3 Kinase Signaling and Chemoresistance in Advanced Ovarian Cancer

Craig P. Carden, Adam Stewart, Parames Thavasu, Emma Kipps, Lorna Pope, Mateus Crespo, Susana Miranda, Gerhardt Attard, Michelle D. Garrett, Paul A. Clarke, Paul Workman, Johann S. de Bono, Martin Gore, Stan B Kaye, Udai Banerji
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2012) 11 (7): 1609–1617.
DOI: https://doi.org/10.1158/1535-7163.MCT-11-0996
Published: 05 July 2012
View article
PDF
Includes: Supplementary data
Journal Articles

Abstract A37: Development of biologics targeting soluble ligands: Novel biomarker and PK-PD analyzes examining free and total ligand profile following treatment with carlumab (anti-CCL2 mAb).

Shobha Seetharam, Thomas A. Puchalski, Thomas McIntosh, Shalini Chaturvedi, Fitzroy Dawkins, Yusri Elsayed, Anthony W. Tolcher, Kenneth J. Pienta, Johann S. de Bono, Chris H. Takimoto
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2011) 10 (11_Supplement): A37.
DOI: https://doi.org/10.1158/1535-7163.TARG-11-A37
Published: 12 November 2011
View article
Journal Articles

Abstract CN08-02: Androgens, biomarkers, and abiraterone.

Johann S. de Bono
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2011) 10 (11_Supplement): CN08-02.
DOI: https://doi.org/10.1158/1535-7163.TARG-11-CN08-02
Published: 12 November 2011
View article
Journal Articles

Targeting Insulin-Like Growth Factor Signaling: Rational Combination Strategies

David Olmos, Bristi Basu, Johann S. de Bono
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2010) 9 (9): 2447–2449.
DOI: https://doi.org/10.1158/1535-7163.MCT-10-0719
Published: 08 September 2010
View article
PDF
Includes: Supplementary data
Journal Articles

Targeting the HGF/c-Met Axis: State of Play

Timothy A. Yap, Johann S. de Bono
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2010) 9 (5): 1077–1079.
DOI: https://doi.org/10.1158/1535-7163.MCT-10-0122
Published: 09 May 2010
View article
PDF
Journal Articles

Abstract B137: Pharmacokinetics and pharmacodynamic biomarkers for the dual PI3K/mTOR inhibitor GDC‐0980: Initial phase I evaluation

Andrew J. Wagner, Howard A. Burris, III, Johann S. de Bono, Gordon C. Jayson, Johanna C. Bendell, Carlos Gomez‐Roca, Saoirse Dolly, Ying‐Kiat Zee, Joseph A. Ware, Yibing Yan, Kathryn Mazina, Mika Derynck, Scott Holden, Jean‐Charles Soria
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2009) 8 (12_Supplement): B137.
DOI: https://doi.org/10.1158/1535-7163.TARG-09-B137
Published: 10 December 2009
View article
Journal Articles

Abstract B135: First‐in‐man, first‐in‐class phase I study of two schedules of MK‐2206, a novel oral Akt inhibitor, in patients (pts) with advanced solid tumors, including ovarian and castration resistant prostate cancer (CRPC)

Timothy A. Yap, Kyriakos Papadopoulos, Ivy Fearen, Christopher Carpenter, Liliana Delgado, Adekemi Taylor, Julia Domsch, David Olmos, Andre T. Brunetto, Daniel S. Tan, Shaun Decordova, Simon P. Heaton, Michelle D. Garrett, Amita Patnaik, Daniel Sullivan, Li Yan, Johann S. de Bono, Anthony W. Tolcher
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2009) 8 (12_Supplement): B135.
DOI: https://doi.org/10.1158/1535-7163.TARG-09-B135
Published: 10 December 2009
View article
Journal Articles

Predictive biomarkers for targeting insulin-like growth factor-I (IGF-I) receptor

Craig P. Carden, L. Rhoda Molife, Johann S. de Bono
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2009) 8 (8): 2077–2078.
DOI: https://doi.org/10.1158/1535-7163.MCT-09-0641
Published: 14 August 2009
View article
PDF
Includes: Supplementary data